A Randomized, Double-Blind, Double-Dummy, Multicenter Trial of Voriconazole and Fluconazole in the Treatment of Esophageal Candidiasis in Immunocompromised Patients

The efficacy, safety, and tolerability of voriconazole and fluconazole were compared in 391 immunocompromised patients with mycology- and biopsy-proven esophageal candidiasis. Primary efficacy analysis (256 patients) of esophageal treatment as assessed by esophagoscopy revealed success rates of 98.3...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical infectious diseases 2001-11, Vol.33 (9), p.1447-1454
Hauptverfasser:	Ally, R., Schürmann, D., Kreisel, W., Carosi, G., Aguirrebengoa, K., Dupont, B., Hodges, M., Troke, P., Romero, A. J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged AIDS Antibiotics. Antiinfectious agents. Antiparasitic agents Antifungal agents Antifungal Agents - adverse effects Antifungal Agents - therapeutic use Antifungals Azoles Biological and medical sciences Candidiasis Candidiasis - drug therapy Candidiasis - microbiology Candidiasis - pathology Consumer Product Safety Double-Blind Method Esophageal Diseases - drug therapy Esophageal Diseases - microbiology Esophageal Diseases - pathology Esophagitis Female Fluconazole - adverse effects Fluconazole - therapeutic use Fungal infections Humans Immunocompromised Host Immunocompromised hosts Infections Major Articles Male Medical sciences Microbial Sensitivity Tests Middle Aged Pharmacology. Drug treatments Pyrimidines - adverse effects Pyrimidines - therapeutic use Symptoms Treatment Outcome Triazoles Triazoles - adverse effects Triazoles - therapeutic use Voriconazole
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!